Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae

NACompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

October 19, 2016

Primary Completion Date

January 4, 2019

Study Completion Date

January 4, 2019

Conditions
Gonococcal Infection
Interventions
DRUG

Ciprofloxacin

Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.

Trial Locations (9)

19146

Philadelphia Department of Public Health - Health Center 1, Philadelphia

20005

Whitman-Walker Health, Washington D.C.

39202

University of Mississippi - Infectious Diseases, Jackson

70119

Louisiana State University Health Sciences Center, New Orleans

90027

AIDS Healthcare Foundation Wellness Center - Hollywood, Los Angeles

92103

University of California, San Diego Health - Owen Clinic, San Diego

90028-6213

Los Angeles Lesbian Gay Bisexual/Transgender Center, Los Angeles

92103-8208

University of California, San Diego - Antiviral Research Center, San Diego

94103-4030

San Francisco Department of Public Health - San Francisco City Clinic, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02961751 - Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae | Biotech Hunter | Biotech Hunter